Cite
MLA Citation
Marisa A Fuse et al.. “Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development.” Neuro-oncology, vol. 21, no. 4, 2019, pp. 486–497. http://access.bl.uk/ark:/81055/vdc_100092353575.0x000016